» Articles » PMID: 34299114

The Multifactorial Progression from the Islet Autoimmunity to Type 1 Diabetes in Children

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jul 24
PMID 34299114
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Type 1 Diabetes (T1D) results from autoimmune destruction of insulin producing pancreatic ß-cells. This disease, with a peak incidence in childhood, causes the lifelong need for insulin injections and necessitates careful monitoring of blood glucose levels. However, despite the current insulin therapies, it still shortens life expectancy due to complications affecting multiple organs. Recently, the incidence of T1D in childhood has increased by 3-5% per year in most developed Western countries. The heterogeneity of the disease process is supported by the findings of follow-up studies started early in infancy. The development of T1D is usually preceded by the appearance of autoantibodies targeted against antigens expressed in the pancreatic islets. The risk of T1D increases significantly with an increasing number of positive autoantibodies. The order of autoantibody appearance affects the disease risk. Genetic susceptibility, mainly defined by the human leukocyte antigen (HLA) class II gene region and environmental factors, is important in the development of islet autoimmunity and T1D. Environmental factors, mainly those linked to the changes in the gut microbiome as well as several pathogens, especially viruses, and diet are key modulators of T1D. The aim of this paper is to expand the understanding of the aetiology and pathogenesis of T1D in childhood by detailed description and comparison of factors affecting the progression from the islet autoimmunity to T1D in children.

Citing Articles

Risk for progression to type 1 diabetes in first-degree relatives under 50 years of age.

Urrutia I, Martinez R, Calvo B, Marcelo I, Saso-Jimenez L, Martinez de Lapiscina I Front Endocrinol (Lausanne). 2024; 15:1411686.

PMID: 39188918 PMC: 11345149. DOI: 10.3389/fendo.2024.1411686.


Long-Term Survival and Induction of Operational Tolerance to Murine Islet Allografts by Co-Transplanting Cyclosporine A Microparticles and CTLA4-Ig.

Kuppan P, Wong J, Kelly S, Lin J, Worton J, Castro C Pharmaceutics. 2023; 15(9).

PMID: 37765170 PMC: 10537425. DOI: 10.3390/pharmaceutics15092201.


Oral delivery of bi-autoantigens by bacterium-like particles (BLPs) against autoimmune diabetes in NOD mice.

Mao R, Wang J, Xu Y, Wang Y, Wu M, Mao L Drug Deliv. 2023; 30(1):2173339.

PMID: 36719009 PMC: 9891168. DOI: 10.1080/10717544.2023.2173339.


Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models.

Markovics A, Rosenthal K, Mikecz K, Carambula R, Ciemielewski J, Zimmerman D Biomedicines. 2022; 10(1).

PMID: 35052724 PMC: 8772713. DOI: 10.3390/biomedicines10010044.

References
1.
Barzaghi F, Passerini L, Bacchetta R . Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front Immunol. 2012; 3:211. PMC: 3459184. DOI: 10.3389/fimmu.2012.00211. View

2.
Lamb M, Yin X, Zerbe G, Klingensmith G, Dabelea D, Fingerlin T . Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young. Diabetologia. 2009; 52(10):2064-71. PMC: 2813468. DOI: 10.1007/s00125-009-1428-2. View

3.
Ilonen J, Lempainen J, Hammais A, Laine A, Harkonen T, Toppari J . Primary islet autoantibody at initial seroconversion and autoantibodies at diagnosis of type 1 diabetes as markers of disease heterogeneity. Pediatr Diabetes. 2017; 19(2):284-292. DOI: 10.1111/pedi.12545. View

4.
Bingley P, Boulware D, Krischer J . The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes. Diabetologia. 2015; 59(3):542-9. PMC: 4742489. DOI: 10.1007/s00125-015-3830-2. View

5.
Herold K, Bundy B, Long S, Bluestone J, DiMeglio L, Dufort M . An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019; 381(7):603-613. PMC: 6776880. DOI: 10.1056/NEJMoa1902226. View